| | | | |
CUSIP No. 28059Q103 | | Schedule 13G | | |
(a) Name of Issuer:
Edify Acquisition Corp. (the “Issuer”).
(b) Address of the Issuer’s Principal Executive Offices:
888 7th Avenue, Floor 29, New York, NY 10106
(a) Name of Person Filing:
This joint statement on Schedule 13G is being filed by FFI Fund Ltd. (“FFI”), FYI Ltd. (“FYI”), Olifant Fund, Ltd. (“Olifant” and collectively with FFI and FYI, the “Funds”), and Bracebridge Capital, LLC (the “Investment Manager”), who are collectively referred to as the “Reporting Persons.” The Investment Manager is the investment manager of each of the Funds. The Reporting Persons have entered into a Joint Filing Agreement, dated as of June 14, 2023, a copy of which is filed with this Schedule 13G as Exhibit 99.1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.
(b) Address of Principal Business Office:
The principal business office of the Reporting Persons is 888 Boylston Street, 15th Floor, Boston, Massachusetts 02199.
(c) Citizenship:
The Investment Manager is a Delaware limited liability company. Each of the Funds is a Cayman Islands exempted company.
(d) Title and Class of Securities:
Common Stock, par value $0.0001 per share, of the Issuer (the “Common Stock”).
(e) CUSIP Number:
28059Q103
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
N/A.
(a). Amount beneficially owned:
As of the date hereof, the Reporting Persons, in the aggregate, may be deemed to beneficially own 500,000 shares of Common Stock, which are included within an equal number of units issued by Edify Acquisition Corp. (the “Issuer”) on January 20, 2021 (the “Units”). Each Unit consists of one share of Common Stock, and one-half of one redeemable warrant (the “Redeemable Warrants”). The Redeemable Warrants have an exercise price of $11.50 per share of Common Stock. The Redeemable Warrants are not currently exercisable and become exercisable 30 days after the Issuer’s initial business combination, provided that certain additional conditions are met. The Redeemable Warrants will expire five years after the completion of the Issuer’s initial business combination. The number of